DOCSLIB.ORG

Pityriasis Rosea

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pityriasis Rosea BMJ 2015;351:h5233 doi: 10.1136/bmj.h5233 (Published 29 October 2015) Page 1 of 6 Practice PRACTICE PRACTICE POINTER Pityriasis rosea Samantha Eisman consultant dermatologist, Rodney Sinclair professor in dermatology Sinclair Dermatology, Melbourne, VIC, 3002, Australia Pityriasis rosea is an acute exanthem that may cause patients great anxiety but is self limiting and resolves within one to three How does pityriasis rosea present? months.1 It is a distinctive erythematous oval scaly eruption of Pityriasis rosea begins in 40-76% of patients with a single herald the trunk and limbs, with minimal constitutional symptoms. patch—an asymptomatic thin oval scaly plaque often on the What causes pityriasis rosea? trunk (fig 1⇓).7 Multiple herald patches may also occur.8 The patch is usually well demarcated, 2-4 cm in diameter, The cause of pityriasis rosea is uncertain but epidemiological erythematous, salmon coloured, or hyperpigmented. A fine (seasonal variation and clustering in communities) and clinical collarette of scale is attached to the periphery of the plaque with features suggest an infective agent. Light and electron its free edge extending internally. Within days to three weeks microscopy findings suggest infection with human herpesviruses 2 the second phase begins—the appearance of numerous smaller 6 and 7 (HHV-6/7). These viral antigens have been detected lesions, which are similar in configuration but occur along the in skin lesions by immunohistochemistry and their DNA has lines of cleavage of the trunk (Christmas tree pattern; figs 2⇓ been isolated from non-lesional skin, peripheral blood 3 and 3⇓). The rash typically lasts five weeks; it resolves within mononuclear cells, serum, and saliva samples. HHV-6 and eight weeks in 80% of patients but can last for five months.8 HHV-7 may also interact with each other, explaining recurrences After recovery, the affected skin may be hyperpigmented or and atypical presentations. hypopigmented but will not scar. Drugs and pityriasis rosea Not all patients present with typical morphology and distribution; 20% present with atypical disease,9 in which A pityriasis rosea-like eruption has been attributed to several morphology, size, distribution, number, site, severity, and drugs (box 1), mostly in single case reports, as identified in our disease course are unusual. The more common atypical variants scan of the literature. In the drug induced form there is no herald include unilateral, inverse, lichenoid, vesicular, papular, patch, individual lesions tend to be violet-red in colour, pruritus purpuric, erythema multiforme-like, and urticarial types (fig is more severe, and eosinophilia may be present. It has been 4⇓).9 speculated that drugs can trigger HHV-6 or HHV-7. However Constitutional symptoms are usually absent but a recent case a small series of 12 cases found HHV-6 DNA in the plasma of series of 52 patients found prodromal symptoms (fever, one of 10 patients only, and all patients recovered within two 4 headache, arthralgia, cough, vomiting, or lymphadenopathy) in weeks of discontinuing the drug. 59.6%.10 Pruritus is variable in intensity and frequency and has If the rash lasts longer than two months consider whether been reported to affect 50% of patients.5 Topical treatments of medication may be responsible (box 1). If a drug is suspected all forms have been reported to exacerbate the pruritus.8 but is medically indicated, refer the patient to a dermatologist Relapse rates of 1.8-3.7% have been reported, but these are and, if appropriate, a relevant specialist (such as a neurologist probably underestimates.8 Multiple recurrences are about antiepileptic treatment) to help with decisions about uncommon—three or more episodes have been reported in only whether to stop the drug. eight patients, and the maximum number reported is five.11 Who gets pityriasis rosea? How do we diagnose pityriasis rosea? Pityriasis rosea mainly affects adolescents and young adults 5 Pityriasis rosea can be difficult to diagnose, especially at the aged 10-35 years. A meta-analysis showed an incidence of onset of symptoms. Other non-specific viral exanthems can be 0.68/100 dermatology patients in specialised settings and 6 mistaken for pityriasis rosea and the differential diagnosis is prevalence has been estimated at 1.3% people in the community. wide (table⇓). No non- invasive tests can confirm the diagnosis. Correspondence to: S Eisman [email protected] For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe BMJ 2015;351:h5233 doi: 10.1136/bmj.h5233 (Published 29 October 2015) Page 2 of 6 PRACTICE Box 1: Medications reported to be implicated in pityriasis rosea-like eruptions (based on our scan of the literature) • Antibiotics/antifungals: metronidazole, pristinamycin, terbinafine • Antidepressants/anxiolytics: nortriptyline, barbiturates, bupropion • Antiepileptic: lamotrigine • Antihypertensives: angiotensin converting enzyme inhibitors (captopril), clonidine, hydrochlorothiazide, atenolol • Antipsychotics: asenapine, clozapine • Biological agents: adalimumab, rituximab • Metals: arsenic, bismuth, gold • Vaccines: hepatitis B, H1N1 influenza, yellow fever, BCG, diphtheria, smallpox, pneumococcus, human papillomavirus • Others: isotretinoin, non-steroidal anti-inflammatory drugs, omeprazole A Cochrane review noted that the diagnosis is clinical and that clinic may be necessary. Although evidence is contradictory, various investigators have used different inclusion and exclusion many dermatologists will consider a monitored trial of ultraviolet criteria in their studies, making systematic reviews and B phototherapy for more aggressive eruptions. meta-analyses difficult.5 For this reason, diagnostic criteria have 12 Patient distress or request for referral to a dermatologist should been proposed for typical and atypical pityriasis rosea (box 2). also be taken into account. Their reliability and applicability in all ethnic groups is as yet uncertain. Methods Skin biopsy is not advocated in typical pityriasis rosea; however, histological examination shows non-specific but similar changes We undertook a literature review using the search term in the herald patch and secondary lesions.10 “pityriasis rosea”. We searched Medline, PubMed, and the Cochrane Library. Because the diagnosis is clinical and Pityriasis rosea in children and pregnancy investigators have adopted different inclusion and exclusion criteria in their studies, meta-analysis of previous reports and Reports suggest that 6-10.5% of patients with pityriasis rosea studies is difficult and overall quality of evidence is weak. are under 10 years of age. Children may present with papular Where possible, randomised double blind placebo controlled lesions (33%), and in those with darker skin, residual studies were reviewed; however, owing to their paucity, case hyperpigmentation (48%) may persist.8 States of studies and case reports were also included but were referred immunosuppression can favour reactivation of HHV-6 or to as such in the text. HHV-7. Because the immune response is altered during pregnancy, there is a risk of viral reactivation. A series of 61 Contributors: All authors helped draft the article and have approved the patients found an increased rate of miscarriage in women who final version to be published. SE is guarantor. develop pityriasis rosea in the first 15 weeks’ gestation, so closer Competing interests: We have read and understood BMJ policy on 13 follow-up of these women is recommended. declaration of interests and declare: nil relevant. Provenance and peer review: Commissioned; externally peer reviewed. How can we treat it? Patient consent for fig 2 obtained. Explain to patients that pityriasis rosea is a self limiting 1 Chuh AA, Chan HH. Effect on quality of life in patients with pityriasis rosea: is it associated condition that is not contagious and usually resolves within one with rash severity? Int J Dermatol 2005;44:372-7. to three months. Treatment is usually symptomatic, and there 2 Chuh AA, Chiu SS, Peiris JS. Human herpesvirus 6 and 7 DNA in peripheral blood is currently no good evidence for one specific treatment. A 2007 leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: a prospective case control study. Acta Derm Venereol 2001;81:289-90. Cochrane review retrieved four trials (three randomised 3 Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic controlled trials and one partially randomised controlled trial) active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol 2002;119:793-7. and found no adequate evidence for or against the effectiveness 4 Drago F, Broccolo F, Agnoletti A, et al. Pityriasis rosea and pityriasis rosea-like eruptions. of erythromycin, systemic corticosteroids, systemic J Am Acad Dermatol 2014;70:196. 6 5 Chuh AA, Dofitas BL, Comisel GG, et al. Interventions for pityriasis rosea. Cochrane antihistamine, and intravenous glycyrrhizin. It recommended Database Syst Rev 2007;2:CD005068. further randomised control trials be conducted. Various other 6 Chuh AA, Zawar V, Law M, et al. Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, treatment modalities have been tried without evidence of and papular-purpuric gloves and socks syndrome: a brief review and arguments for effectiveness including natural sunlight, ultraviolet phototherapy,
Load more

Recommended publications
  • Cutaneous Manifestations of COVID-19: a Systematic Review and Analysis of Individual Patient-Level Data
    Volume 26 Number 12| December 2020 Dermatology Online Journal || Review 26(12):2 Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data David S Lee1 MD, Paradi Mirmirani2,3 MD, Patrick E McCleskey4 MD, Majid Mehrpouya5 PhD, Farzam Gorouhi6,7 MD Affiliations: 1Department of Dermatology, The Permanente Medical Group, Pleasanton, California, USA, 2Department of Dermatology, University of California, San Francisco, California, USA, 3Department of Dermatology, The Permanente Medical Group, Vallejo, California, USA, 4Department of Dermatology, The Permanente Medical Group, Oakland, California, USA, 5Faculty of Engineering, University of Calgary, Calgary, Alberta, Canada, 6Department of Dermatology, The Permanente Medical Group, South Sacramento, California, USA, 7Department of Dermatology, University of California, Davis, California, USA Corresponding Author: Farzam Gorouhi MD FAAD, Kaiser Permanente, South Sacramento, 6600 Bruceville Road, Sacramento, CA 95823, Tel: 415-298-1345, Email: [email protected] Introduction Abstract In December 2019, reports from Wuhan, China Distinctive patterns in the cutaneous manifestations described new clusters of patients with severe of COVID-19 have been recently reported. We pneumonia linked to a novel coronavirus strain, now conducted a systematic review to identify case reports and case series characterizing cutaneous referred to as severe acute respiratory syndrome manifestations of confirmed COVID-19. Key coronavirus 2 (SARS-CoV-2), [1]. Coronavirus disease demographic and clinical data from each case were 2019 (COVID-19) has since reached pandemic extracted and analyzed. The primary outcome proportions, with over 12·7 million cases worldwide, measure was risk factor analysis of skin related 566,000 deaths, and 188 countries affected at the outcomes for severe COVID-19 disease.
    [Show full text]
  • Coexistence of Vulgar Psoriasis and Systemic Lupus Erythematosus - Case Report
    doi: http://dx.doi.org/10.11606/issn.1679-9836.v98i1p77-80 Rev Med (São Paulo). 2019 Jan-Feb;98(1):77-80. Coexistence of vulgar psoriasis and systemic lupus erythematosus - case report Coexistência de psoríase vulgar e lúpus eritematoso sistêmico: relato de caso Kaique Picoli Dadalto1, Lívia Grassi Guimarães2, Kayo Cezar Pessini Marchióri3 Dadalto KP, Guimarães LG, Marchióri KCP. Coexistence of vulgar psoriasis and systemic lupus erythematosus - case report / Coexistência de psoríase vulgar e lúpus eritematoso sistêmico: relato de caso. Rev Med (São Paulo). 2019 Jan-Feb;98(1):77-80. ABSTRACT: Psoriasis and Systemic lupus erythematosus (SLE) RESUMO: Psoríase e Lúpus eritematoso sistêmico (LES) são are autoimmune diseases caused by multifactorial etiology, with doenças autoimunes de etiologia multifatorial, com envolvimento involvement of genetic and non-genetic factors. The purpose de fatores genéticos e não genéticos. O objetivo deste relato of this case report is to clearly and succinctly present a rare de caso é expor de maneira clara e sucinta uma associação association of autoimmune pathologies, which, according to some rara de patologias autoimunes, que, de acordo com algumas similar clinical features (arthralgia and cutaneous lesions), may características clínicas semelhantes (artralgia e lesões cutâneas), interfere or delay the diagnosis of its coexistence. In addition, it podem dificultar ou postergar o diagnóstico de sua coexistência. is of paramount importance to the medical community to know about the treatment of this condition, since there is a possibility Além disso, é de suma importância à comunidade médica o of exacerbation or worsening of one or both diseases. The conhecimento a respeito do tratamento desta condição, já que combination of these diseases is very rare, so, the diagnosis existe a possibilidade de exacerbação ou piora de uma, ou de is difficult and the treatment even more delicate, due to the ambas as doenças.
    [Show full text]
  • Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia
    Hindawi Case Reports in Hematology Volume 2017, Article ID 1923607, 4 pages https://doi.org/10.1155/2017/1923607 Case Report Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia Ramesh Kumar Pandey, Sumit Dahal, Kamal Fadlalla El Jack Fadlalla, Shambhu Bhagat, and Bikash Bhattarai Interfaith Medical Center, Brooklyn, NY, USA Correspondence should be addressed to Ramesh Kumar Pandey; [email protected] Received 14 January 2017; Revised 2 March 2017; Accepted 23 March 2017; Published 4 April 2017 Academic Editor: Kazunori Nakase Copyright © 2017 Ramesh Kumar Pandey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction. Acquired thrombotic thrombocytopenic purpura (TTP) has been associated with different autoimmune disorders. However, its association with pernicious anemia is rarely reported. Case Report. A 46-year-old male presented with blood in sputum and urine for one day. The vitals were stable. The physical examination was significant for icterus. Lab tests’ results revealed leukocytosis, macrocytic anemia, severe thrombocytopenia, renal dysfunction, and unconjugated hyperbilirubinemia. He had an elevated LDH, low haptoglobin levels with many schistocytes, nucleated RBCs, and reticulocytes on peripheral smear. Low ADAMTS13 activity (<10%) with elevated ADAMTS13 antibody clinched the diagnosis of severe acquired TTP,and plasmapheresis was started. There was an initial improvement in his hematological markers, which were however not sustained on discontinuation of plasmapheresis. For his refractory TTP, he was resumed on daily plasmapheresis and Rituximab was started. Furthermore, the initial serum Vitamin B12 and reticulocyte index were low in the presence of anti-intrinsic factor antibody.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Autoinvolutive Photoexacerbated Tinea Corporis Mimicking a Subacute Cutaneous Lupus Erythematosus
    Letters to the Editor 141 low-potency steroids had no eŒect. Our patient was treated 4. Jarrat M, Ramsdell W. Infantile acropustulosis. Arch Dermatol with a modern glucocorticoid which has an improved risk– 1979; 115: 834–836. bene t ratio. The antipruritic and anti-in ammatory properties 5. Kahn G, Rywlin AM. Acropustulosis of infancy. Arch Dermatol of the steroid were increased by applying it in combination 1979; 115: 831–833. 6. Newton JA, Salisbury J, Marsden A, McGibbon DH. with a wet-wrap technique, which has already been shown to Acropustulosis of infancy. Br J Dermatol 1986; 115: 735–739. be extremely helpful in cases of acute exacerbations of atopic 7. Mancini AJ, Frieden IJ, Praller AS. Infantile acropustulosis eczema in combination with (3) or even without topical revisited: history of scabies and response to topical corticosteroids. steroids (8). Pediatr Dermatol 1998; 15: 337–341. 8. Abeck D, Brockow K, Mempel M, Fesq H, Ring J. Treatment of acute exacerbated atopic eczema with emollient-antiseptic prepara- tions using ‘‘wet-wrap’’ (‘‘wet-pyjama’’) technique. Hautarzt 1999; REFERENCES 50: 418–421. 1. Vignon-Pennam en M-D, Wallach D. Infantile acropustulosis. Arch Dermatol 1986; 122: 1155–1160. Accepted November 24, 2000. 2. Duvanel T, Harms M. Infantile Akropustulose. Hautarzt 1988; 39: 1–4. Markus Braun-Falco, Silke Stachowitz, Christina Schnopp, Johannes 3. Oranje AP, Wolkerstorfer A, de Waard-van der Spek FB. Treatment Ring and Dietrich Abeck of erythrodermic atopic dermatitis with ‘‘wet-wrap’’ uticasone Klinik und Poliklinik fu¨r Dermatologie und Allergologie am propionate 0,05% cream/emollient 1:1 dressing.
    [Show full text]
  • Cytomegalovirus Infection Associated with Portal Vein Thrombosis and Thrombocytopenia: a Case Report
    MÉDECINE INTERNE Cytomegalovirus infection associated with portal vein thrombosis and thrombocytopenia: a case report Gianfranco Di Prinzio1, Phung Nguyen Ung2, Anne-Sophie Valschaerts2, Olivier Borgniet2 CMV et Thrombose : We here present the case of portal vein thrombosis in a patient exhibiting symptoms of cytomegalovirus infection, confirmed by un binome sous-estimé serology and polymerase chain reaction (PCR) and complicated by Le Cytomegalovirus (CMV) est thrombocytopenia. The literature reveals growing evidence that responsable d’une infection virale human CMV likely plays a role in thrombotic disorders. However, commune et souvent banale chez le only 11 cases of CMV-induced visceral venous thrombosis have been sujet immunocompétent, mais qui described so far. On the other hand, thrombocytopenia is a well- n’est pas dépourvue de complications potentiellement graves. La thrombose known complication of CMV infection. The patient was successfully porte en est un exemple. Le cas que treated using high-dose immunoglobulins by intravenous route. nous décrivons concerne une patiente atteinte d’une infection à CMV, s’étant révélée par une éruption cutanée et s’étant compliquée d’une thrombose porte, en l’absence de thrombophilie connue. Une thrombopénie auto- A 36-year-old Caucasian woman was admitted to the emergency room immune est la seconde complication of our hospital, complaining since several days of sore throat, cough, survenue dans notre cas. Cet article a pour but de souligner l’enjeu d’un tel fever, headache, and rhinorrhea. She had been unsuccessfully treated diagnostic et de stimuler la réflexion sur with amoxicillin-clavulanate during the week preceding her admission. l’intérêt du dépistage échographique The medication was stopped owing to gastric intolerance.
    [Show full text]
  • Psoriasis and Vitiligo: an Association Or Coincidence?
    igmentar f P y D l o is a o n r r d e u r o s J Solovan C, et al., Pigmentary Disorders 2014, 1:1 Journal of Pigmentary Disorders DOI: 10.4172/jpd.1000106 World Health Academy ISSN: 2376-0427 Letter To Editor Open Access Psoriasis and Vitiligo: An Association or Coincidence? Caius Solovan1, Anca E Chiriac2, Tudor Pinteala2, Liliana Foia2 and Anca Chiriac3* 1University of Medicine and Pharmacy “V Babes” Timisoara, Romania 2University of Medicine and Pharmacy “Gr T Popa” Iasi, Romania 3Apollonia University, Nicolina Medical Center, Iasi, Romania *Corresponding author: Anca Chiriac, Apollonia University, Nicolina Medical Center, Iasi, Romania, Tel: 00-40-721-234-999; E-mail: [email protected] Rec date: April 21, 2014; Acc date: May 23, 2014; Pub date: May 25, 2014 Citation: Solovan C, Chiriac AE, Pinteala T, Foia L, Chiriac A (2014) Psoriasis and Vitiligo: An Association or Coincidence? Pigmentary Disorders 1: 106. doi: 10.4172/ jpd.1000106 Copyright: © 2014 Solovan C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Letter to Editor Dermatitis herpetiformis 1 0.08% Sir, Chronic urticaria 2 0.16% The worldwide occurrence of psoriasis in the general population is Lyell syndrome 1 0.08% about 2–3% and of vitiligo is 0.5-1%. Coexistence of these diseases in the same patient is rarely reported and based on a pathogenesis not Quincke edema 1 0.08% completely understood [1].
    [Show full text]
  • The Coexistence of Systemic Lupus Erythematosus and Psoriasis: Is It Possible?
    CASE REPORT The Coexistence of Systemic Lupus Erythematosus and Psoriasis: Is It Possible? Hendra Gunawan, Awalia, Joewono Soeroso Department of Internal Medicine, Faculty of Medicine, Airlangga University - Dr. Soetomo Hospital, Surabaya, Indonesia Corresponding Author: Prof. Joewono Soeroso, MD., M.Sc, PhD. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University - Dr. Soetomo Hospital. Jl. Mayjen. Prof. Dr. Moestopo 4-6, Surabaya 60132, Indonesia. email: [email protected]; [email protected]. ABSTRAK Lupus eritematosus sistemik (LES) adalah penyakit autoimun kronik eksaserbatif dengan manifestasi klinis yang beragam. Psoriasis vulgaris adalah penyakit kulit yang menyerang 1-3% dari populasi. Patofisiologi mengenai tumpang tindihnya penyakit tersebut belum sepenuhnya diketahui. Hal ini menyebabkan adanya tantangan tersendiri dalam tatalaksana kedua penyakit tersebut. Dua orang laki-laki dengan LES dan psoriasis vulgaris dilaporkan dengan manifestasi klinis eritroderma berulang dengan fotosensitif. Perbaikan klinis dicapai setelah terapi kombinasi metilprednisolon dengan metotrexat. Adanya LES yang tumpang tindih psoriasis vulgaris merupakan suatu fenomena klinis yang langka. Hubungan kedua penyakit tersebut dapat berupa saling mendahului atau tumpang tindih pada suatu waktu yang sama dan memiliki hubungan dengan adanya anti- Ro/SSA. Adanya tumpang tindih dari dua penyakit tersebut memberikan paradigma baru dalam patofisiologi, diagnosis, dan tatalaksana di masa mendatang. Kata kunci: lupus eritematosus sistemik, psoriasis vulgaris, psoriatic artritis, overlap syndrome. ABSTRACT Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with various clinical disorders and frequent exacerbations. Psoriasis vulgaris is a common skin disorder which affect 1-3% of general populations. The pathophysiology regarding the coexistence of these diseases is not fully understood. Therapeutic challenges arise since the treatment one of these diseases may aggravate the other.
    [Show full text]
  • Viral Rashes: New and Old Peggy Vernon, RN, MA, CPNP, DCNP, FAANP C5
    Viral Rashes: New and Old Peggy Vernon, RN, MA, CPNP, DCNP, FAANP C5 Disclosures •There are no financial relationships with commercial interests to disclose Viral Rashes: New and Old •Any unlabeled/unapproved uses of drugs or products referenced will be disclosed Peggy Vernon, RN, MA, CPNP, DCNP, FAANP ©Pvernon2021 ©Pvernon2021 Restrictions Objectives • Permission granted to the 2021 National Nurse • Identify a potential sequelae from hand, foot and Practitioner Symposium and its attendees mouth disease • Describe the pattern of distribution and lesion • All rights reserved. No part of this presentation may description of varicella be reproduced, stored, or transmitted in any form or • Identify a precursor of Henoch Schonlein Purpura by any means without written permission of the author •Contact Peggy Vernon at [email protected] ©Pvernon2021 ©Pvernon2021 Viral Exanthems Morbilliform Exanthems •Morbilliform • Measles (rubeola) •Papular-nodular • Rubella •Vesiculobullous • Roseola •Petechial • Erythema Infectiosum •Purpuric • Pityriasis Rosea • Infectious Mono ©Pvernon2021 ©Pvernon2021 1 Viral Rashes: New and Old Peggy Vernon, RN, MA, CPNP, DCNP, FAANP C5 Measles (Rubeola) MEASLES (RUBEOLA) • Prodrome: fever, malaise, cough, DIFFERENTIAL DIAGNOSIS conjunctivitis. Patient appears quite ill •Other morbilliform eruptions: Rubella, • Koplik’s spots: bluish-white erythema infectiosum, pityriasis rosea, elevations on buccal mucosa infectious mono • Exanthem: erythematous •DRUG maculopapular eruption, from scalp to forehead, posterior
    [Show full text]
  • Drug Treatments in Psoriasis
    Drug Treatments in Psoriasis Authors: David Gravette, Pharm.D. Candidate, Harrison School of Pharmacy, Auburn University; Morgan Luger, Pharm.D. Candidate, Harrison School of Pharmacy, Auburn University; Jay Moulton, Pharm.D. Candidate, Harrison School of Pharmacy, Auburn University; Wesley T. Lindsey, Pharm.D., Associate Clinical Professor of Pharmacy Practice, Drug Information and Learning Resource Center, Harrison School of Pharmacy, Auburn University Universal Activity #: 0178-0000-13-108-H01-P | 1.5 contact hours (.15 CEUs) Initial Release Date: November 29, 2013 | Expires: April 1, 2016 Alabama Pharmacy Association | 334.271.4222 | www.aparx.org | [email protected] SPRING 2014: CONTINUING EDUCATION |WWW.APARX.Org 1 EducatiONAL OBJECTIVES After the completion of this activity pharmacists will be able to: • Outline how to diagnose psoriasis. • Describe the different types of psoriasis. • Outline nonpharmacologic and pharmacologic treatments for psoriasis. • Describe research on new biologic drugs to be used for the treatment of psoriasis as well as alternative FDA uses for approved drugs. INTRODUCTION depression, and even alcoholism which decreases their quality of Psoriasis is a common immune modulated inflammatory life. It is uncertain why these diseases coincide with one another, disease affecting nearly 17 million people in North America and but it is hypothesized that the chronic inflammatory nature of Europe, which is approximately 2% of the population. The highest psoriasis is the underlying problem. frequencies occur in Caucasians
    [Show full text]
  • Pityriasis Rosea Following Influenza
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 280e282 www.jcma-online.com Case Report Pityriasis rosea following influenza (H1N1) vaccination Jeng-Feng Chen, Chien-Ping Chiang, Yu-Fei Chen, Wei-Ming Wang* Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC Received May 3, 2010; accepted November 13, 2010 Abstract Pityriasis rosea is a distinct papulosquamous skin eruption that has been attributed to viral reactivation, certain drug exposures or rarely, vaccination. Herein, we reported a clinicopathlogically typical case of pityriasis rosea that developed after the H1N1 vaccination. With a global H1N1 vaccination program against the pandemic H1N1 influenza, patients should be apprised of the possibility of such rare but benign skin reaction to avoid unnecessary fear. Furthermore, a brief review of the current reported skin adverse events related to the novel H1N1 vaccination in Taiwan is presented here. Copyright Ó 2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved. Keywords: Adverse reaction; H1N1 vaccination; Pandemic; Pityriasis rosea 1. Introduction a herald skin lesion was spotted initially in his left upper thigh followed several days later by the onset of many itchy scaly Pityriasis rosea (PR) is an acute, self-limited, papulosqu- lesions on his trunk and proximal extremities. The first herald amous skin eruption that occurs most commonly among patch developed five days after he underwent H1N1 vaccina- teenagers and young adults.1 Typical clinical presentation is tion (AdimFlu-S (A-H1N1), Adimmune, Taichung, Taiwan).
    [Show full text]
  • Fundamentals of Dermatology Describing Rashes and Lesions
    Dermatology for the Non-Dermatologist May 30 – June 3, 2018 - 1 - Fundamentals of Dermatology Describing Rashes and Lesions History remains ESSENTIAL to establish diagnosis – duration, treatments, prior history of skin conditions, drug use, systemic illness, etc., etc. Historical characteristics of lesions and rashes are also key elements of the description. Painful vs. painless? Pruritic? Burning sensation? Key descriptive elements – 1- definition and morphology of the lesion, 2- location and the extent of the disease. DEFINITIONS: Atrophy: Thinning of the epidermis and/or dermis causing a shiny appearance or fine wrinkling and/or depression of the skin (common causes: steroids, sudden weight gain, “stretch marks”) Bulla: Circumscribed superficial collection of fluid below or within the epidermis > 5mm (if <5mm vesicle), may be formed by the coalescence of vesicles (blister) Burrow: A linear, “threadlike” elevation of the skin, typically a few millimeters long. (scabies) Comedo: A plugged sebaceous follicle, such as closed (whitehead) & open comedones (blackhead) in acne Crust: Dried residue of serum, blood or pus (scab) Cyst: A circumscribed, usually slightly compressible, round, walled lesion, below the epidermis, may be filled with fluid or semi-solid material (sebaceous cyst, cystic acne) Dermatitis: nonspecific term for inflammation of the skin (many possible causes); may be a specific condition, e.g. atopic dermatitis Eczema: a generic term for acute or chronic inflammatory conditions of the skin. Typically appears erythematous,
    [Show full text]